RITUXIMAB IN PRIMARY IMMUNOLOGIC THROMBOCYTOPENIA

The management of certain refractory and corticoresistant forms of ITP often poses a therapeutic problem. The advent of new therapeutic alternatives, notably biotherapy, has offered new opportunities for remission in these patients. Rituximab is the biotherapy of choice in these situations. We have studied the indications for rituximab and the therapeutic response in patients with chronic refractory ITP. Through our experience and a review of the literature we will try to recall the pathophysiology, clinical and biological characteristics of ITP, study the indications and use of rituximab in ITP and report the other biotherapies used in ITP and their indications.